9581 Background: For several cancers, response to neoadjuvant therapy (NAT) correlates
with survival. Targeted and immune therapies achieve high response rates and durable …

9503 Background: Pathological complete response (pCR) to neoadjuvant systemic therapy
(NST) correlates with survival, and is recognized as a path to regulatory approval in several …

The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Objective: To determine the feasibility and impact of neoadjuvant therapy (NT) in patients
who present with advanced melanoma amenable to surgical resection. Summary …

Abstract Purpose of Review Neoadjuvant therapy in melanoma is an area of active
investigation with numerous completed and ongoing trials studying a variety of therapeutic …

Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that
ranges from approximately 40% to 90% at 5 years following surgical management alone …

Simple Summary Neo-adjuvant systemic (NAS) therapy for melanoma is leading the way in
immunotherapy for oncology. There is both a strong biological rationale to support NAS …

Since the advent of effective systemic therapy, quantum changes have occurred in the
multidisciplinary management strategies used for patients with American Joint Committee on …

Tremendous progress has been made in treating patients with metastatic melanoma over
the past decade. In that timeframe, the FDA has approved 12 novel treatments for patients …

LBA2 Background: Standard of care (SOC) for resectable, macroscopic stage III melanoma
is therapeutic lymph node dissection (TLND) followed by adjuvant (adj) therapy with …